Company: BDRX
Filing Date: 2025-04-29
Form Type: POS AM
Source: 0001214659-25-006581
Chunk: 9

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-29
Form: POS AM
Chunk 9
---
0.001
nominal value each into one ordinary share of £0.00005 nominal value and 19 C Deferred Shares of £0.00005 nominal value each,
each the November Subdivision, which became effective on November 25, 2024 and (y) adopt new articles of association, or the Articles
of Association, which make consequential amendments to the existing articles of association of the Company to reflect the November Subdivision.
As is standard for deferred shares, each B Deferred Share and C Deferred Share has very limited rights and is effectively valueless. The
B Deferred Shares and C Deferred Shares have the rights and restrictions as set out in the Articles of Association and do not entitle
the holder thereof to receive notice of or attend and vote at any general meeting of the Company or to receive a dividend or other distribution.

| 2 |

The change in the number of
Ordinary Shares resulting from the reverse stock split and change in the number of Depositary Shares (and the underlying Ordinary Shares)
resulting from the change in ratio, including any changes resulting from fractional Depositary Shares not being issued to holders in connection
with the Depositary Share ratio change, has been applied retroactively to all share and per share amounts presented in this prospectus,
to the extent applicable. As a result of retroactively applying changes resulting from fractional Depositary Shares not being issued to
holders in connection with the Depositary Share ratio change, the amount of Ordinary Shares issued in prior transactions may not equal
the amount of Depositary Shares such Depositary Shares are currently exercisable for.

<div align='center'>MARKET AND INDUSTRY DATA</div>

Market data and certain industry
data and forecasts used throughout this prospectus were obtained from sources we believe to be reliable, including market research databases,
publicly available information, reports of governmental agencies, and industry publications and surveys. We have relied on certain data
from third-party sources, including internal surveys, industry forecasts, and market research, which we believe to be reliable based on
our management’s knowledge of the industry. While we are not aware of any misstatements regarding the industry data presented in
this prospectus, our estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed
under the heading “Risk Factors” and elsewhere in this prospectus.

Solely
for convenience, the trademarks and trade names in this prospectus may be referred to without the ® and ™ symbols, but such
references should not be construed